Research programme: neural stem cell therapies - ReNeuron

Drug Profile

Research programme: neural stem cell therapies - ReNeuron

Alternative Names: CTX cells - ReNeuron; ReN 004; ReN 005

Latest Information Update: 21 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ReNeuron
  • Class Stem cell therapies
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Huntington's disease; Neurological disorders; Parkinson's disease

Most Recent Events

  • 28 Nov 2016 StemCells has been acquired by Microbot Medical
  • 15 Aug 2013 No development reported - Preclinical for Huntington's disease, Parkinson's disease and other neurological disorders in United Kingdom (Intracranial)
  • 15 Aug 2013 ReNeuron plans a phase I trial for Peripheral arterial occlusive disorders in United Kingdom (NCT01916369)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top